Our technology is a simple visual field analyzer, consisting of a software platform linked to any flat screen display unit; tablet, computer, even larger mobile phones. We will be the first to provide accurate visual field screening on a simple, inexpensive, universally available screen with accuracy equivalent to current “gold standard” hemispherical analyzers. Visual field testing remains critical for identifying glaucoma in patients and assessing how far the disease has progressed, as well as for assessing quality of life issues including a patient’s ability to perform daily life activities.
We offer an all-inclusive, simple, screening service and charge a service fee for each patient exam. Our service includes the screen, operating software, billing/financial software and links to medical records. Data is protected in a HIPAA-compliant cloud-based software platform. All our distribution partners need to do is hand the patient the tablet and run the program for five minutes or less. The results are available instantly, allowing immediate direct referrals to eye care professionals.
Dr. Gautam Thor, CEO and STTR P.I., has a Ph.D. in Neurobiology and over 30 years' experience in Vision Research, both in academia as well as in the corporate sector. He has also obtained certification to be a research clinical coordinator with IR8-approved proposals.
Retinal Registry was launched as a sole proprietorship, and, has since been incorporated, to investigate and develop novel vision-related diagnostic test procedures and health care solutions. Our core competencies lie in developing customized testing and interpretation software for a range of ophthalmic and neuro-ophthalmic applications. Retinal Registry has not commercialized or licensed the system or any of its sub-components.
The following patent application has been filed as a Utility Non-Provisional: System and Method for Visual Field Assessment, US Patent Application Number 2022 0296092, filed on September 22, 2022.
Retinal Registry will be relying on consultants for regulatory affairs, test platform trials, eye-tracker development and software integration: Jennifer Cantor, MBA, RAC - Centaur Consulting LLC, River Falls, WI Nazlee Zebardast, Medical Director, Glaucoma Imaging, Mass. Eye & Ear; Assistant Professor of Ophthalmology, Harvard Medical School, Boston, MA Peter Jones, MD, Ph.D. - School of Health & Psychological Sciences, Department of Optometry and Visual Sciences, City University of London, UK Walter Lohnes, Business Development Director, Integrated Computer Solutions, Waltham, MA
The company's Panel of Advisors comprises physician-scientists, retinal surgeons, ophthalmologists and glaucoma specialists, all of whom have consented to provide clinical insights and assist in conducting clinical trials with patient-volunteers. This expert group of eye-care professionals will provide oversight and feedback, especially regarding the protocols employed and test-data validation: Dr. Hema Ramkumar, Ophthalmologist & Retinal Specialist, Orange County, CA Dr. Andrew Camp, Shiley Eye Institute, San Diego, CA Dr. Andrew Lee, Bethel Eye Center, Los Angeles, CA Dr. Sasan Moghimi, UC San Diego Health, San Diego, CA Dr. Christopher Bowd, Hamilton Glaucoma Center, San Diego, CA